Autor: |
Peter I. Darroch, Arie Dagan, Tami Granot, Xingxuan He, Shimon Gatt, Edward H. Schuchman |
Jazyk: |
angličtina |
Rok vydání: |
2005 |
Předmět: |
|
Zdroj: |
Journal of Lipid Research, Vol 46, Iss 11, Pp 2315-2324 (2005) |
Druh dokumentu: |
article |
ISSN: |
0022-2275 |
DOI: |
10.1194/jlr.M500136-JLR200 |
Popis: |
We report the synthesis and characterization of a novel thiourea derivative of sphingomyelin (AD2765). In vitro assays using pure enzyme and/or cell extracts revealed that this compound inhibited the hydrolysis of BODIPY-conjugated or 14C-labeled sphingomyelin by acid sphingomyelinase and Mg2+-dependent neutral sphingomyelinase. Studies in normal human skin fibroblasts further revealed that AD2765 was taken up by cells and inhibited the hydrolysis of BODIPY-conjugated sphingomyelin in situ. In situ and in vitro studies also showed that this compound inhibited the synthesis of sphingomyelin from BODIPY-conjugated ceramide. The specificity of AD2765 for enzymes involved in sphingomyelin metabolism was demonstrated by the fact that it had no effect on the hydrolysis of BODIPY-conjugated ceramide by acid ceramidase or on the synthesis of BODIPY-conjugated glucosylceramide from BODIPY-conjugated ceramide. The overall effect of AD2765 on sphingomyelin metabolism was concentration-dependent, and treatment of normal human skin fibroblasts or cancer cells with this compound at concentrations > 10 μM led to an increase in cellular ceramide and cell death.Thus, AD2765 might be used to manipulate sphingomyelin metabolism in various ways, potentially to reduce substrate accumulation in cells from types A and B Niemann-Pick disease patients, and/or to affect the growth of human cancer cells. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|